Verrica Pharmaceuticals Reports Q3 2026 Results with Strong YCANTH Product Growth
Verrica Pharmaceuticals (VRCA) reported third-quarter 2026 revenue of $6.9 million. While total revenue decreased year-over-year due to the absence of a prior-year milestone payment from Torii Pharmaceutical, core U.S. YCANTH net product revenue grew significantly, reaching $5.7 million—a 57.9% increase compared to the same period last year. The company demonstrated improved operational efficiency with gross product margins rising to 89.8%. Despite a GAAP net loss of $12.4 million, management highlighted an extended cash runway into late 2027, supported by a $15 million available credit commitment. This liquidity is intended to fund operations through upcoming pivotal clinical data readouts. Clinical development remains a primary focus, with enrollment complete for the COVE-2 Phase III common warts trial, which is expected to yield top-line data in Q1 2027. Additionally, early efficacy results from the VP-315 Phase II study showed high response rates in treating basal cell carcinoma lesions.
Tickers: $VRCA
Topics: Net Loss Product Growth R&D Expense Revenue
Read the full article at Motley Fool
Part of the story Verrica Pharmaceuticals Reports Q3 2026 Results with Strong YCANTH Product Growth (2 articles)